NASDAQ:MMSI

Merit Medical Systems Competitors

$61.84
+0.89 (+1.46 %)
(As of 04/14/2021 01:25 PM ET)
Add
Compare
Today's Range
$61.33
Now: $61.84
$62.00
50-Day Range
$52.56
MA: $57.81
$61.50
52-Week Range
$33.16
Now: $61.84
$61.80
Volume3,207 shs
Average Volume289,956 shs
Market Capitalization$3.44 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.21

Competitors

Merit Medical Systems (NASDAQ:MMSI) Vs. ALGN, WST, COO, XRAY, HAE, and QDEL

Should you be buying MMSI stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Merit Medical Systems, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), and Quidel (QDEL).

Align Technology (NASDAQ:ALGN) and Merit Medical Systems (NASDAQ:MMSI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares Align Technology and Merit Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Align Technology76.00%68.99%46.64%
Merit Medical Systems-3.05%9.02%4.91%

Analyst Recommendations

This is a summary of current recommendations for Align Technology and Merit Medical Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Align Technology13902.62
Merit Medical Systems01702.88

Align Technology presently has a consensus price target of $501.3333, indicating a potential downside of 16.21%. Merit Medical Systems has a consensus price target of $64.3750, indicating a potential upside of 4.13%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts clearly believe Merit Medical Systems is more favorable than Align Technology.

Risk and Volatility

Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Institutional and Insider Ownership

85.8% of Align Technology shares are owned by institutional investors. Comparatively, 99.5% of Merit Medical Systems shares are owned by institutional investors. 1.2% of Align Technology shares are owned by company insiders. Comparatively, 4.7% of Merit Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Align Technology and Merit Medical Systems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$2.41 billion19.70$442.78 million$4.96120.77
Merit Medical Systems$994.85 million3.46$5.45 million$1.4642.36

Align Technology has higher revenue and earnings than Merit Medical Systems. Merit Medical Systems is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Align Technology beats Merit Medical Systems on 10 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and Merit Medical Systems (NASDAQ:MMSI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Profitability

This table compares West Pharmaceutical Services and Merit Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
Merit Medical Systems-3.05%9.02%4.91%

Analyst Recommendations

This is a summary of current recommendations for West Pharmaceutical Services and Merit Medical Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
Merit Medical Systems01702.88

West Pharmaceutical Services presently has a consensus price target of $310.00, indicating a potential upside of 2.12%. Merit Medical Systems has a consensus price target of $64.3750, indicating a potential upside of 4.13%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts clearly believe Merit Medical Systems is more favorable than West Pharmaceutical Services.

Risk and Volatility

West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Institutional and Insider Ownership

92.6% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 99.5% of Merit Medical Systems shares are owned by institutional investors. 1.6% of West Pharmaceutical Services shares are owned by company insiders. Comparatively, 4.7% of Merit Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares West Pharmaceutical Services and Merit Medical Systems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion12.17$241.70 million$3.2493.59
Merit Medical Systems$994.85 million3.46$5.45 million$1.4642.36

West Pharmaceutical Services has higher revenue and earnings than Merit Medical Systems. Merit Medical Systems is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Summary

West Pharmaceutical Services beats Merit Medical Systems on 8 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and Merit Medical Systems (NASDAQ:MMSI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Institutional and Insider Ownership

95.8% of The Cooper Companies shares are owned by institutional investors. Comparatively, 99.5% of Merit Medical Systems shares are owned by institutional investors. 1.4% of The Cooper Companies shares are owned by company insiders. Comparatively, 4.7% of Merit Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares The Cooper Companies and Merit Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
Merit Medical Systems-3.05%9.02%4.91%

Earnings & Valuation

This table compares The Cooper Companies and Merit Medical Systems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion7.86$238.40 million$9.6440.31
Merit Medical Systems$994.85 million3.46$5.45 million$1.4642.36

The Cooper Companies has higher revenue and earnings than Merit Medical Systems. The Cooper Companies is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for The Cooper Companies and Merit Medical Systems, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04602.60
Merit Medical Systems01702.88

The Cooper Companies presently has a consensus price target of $384.25, indicating a potential downside of 1.11%. Merit Medical Systems has a consensus price target of $64.3750, indicating a potential upside of 4.13%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts clearly believe Merit Medical Systems is more favorable than The Cooper Companies.

Risk and Volatility

The Cooper Companies has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Summary

The Cooper Companies beats Merit Medical Systems on 8 of the 14 factors compared between the two stocks.

Merit Medical Systems (NASDAQ:MMSI) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

99.5% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are owned by institutional investors. 4.7% of Merit Medical Systems shares are owned by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Merit Medical Systems and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merit Medical Systems-3.05%9.02%4.91%
DENTSPLY SIRONA-1.40%7.13%4.13%

Earnings and Valuation

This table compares Merit Medical Systems and DENTSPLY SIRONA's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$994.85 million3.46$5.45 million$1.4642.36
DENTSPLY SIRONA$4.03 billion3.55$262.90 million$2.4526.64

DENTSPLY SIRONA has higher revenue and earnings than Merit Medical Systems. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Merit Medical Systems and DENTSPLY SIRONA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merit Medical Systems01702.88
DENTSPLY SIRONA15702.46

Merit Medical Systems currently has a consensus target price of $64.3750, indicating a potential upside of 4.13%. DENTSPLY SIRONA has a consensus target price of $55.3333, indicating a potential downside of 15.25%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts clearly believe Merit Medical Systems is more favorable than DENTSPLY SIRONA.

Volatility & Risk

Merit Medical Systems has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Summary

Merit Medical Systems beats DENTSPLY SIRONA on 8 of the 13 factors compared between the two stocks.

Merit Medical Systems (NASDAQ:MMSI) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

99.5% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 96.2% of Haemonetics shares are owned by institutional investors. 4.7% of Merit Medical Systems shares are owned by insiders. Comparatively, 1.6% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Merit Medical Systems and Haemonetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merit Medical Systems-3.05%9.02%4.91%
Haemonetics11.76%22.85%10.40%

Earnings and Valuation

This table compares Merit Medical Systems and Haemonetics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$994.85 million3.46$5.45 million$1.4642.36
Haemonetics$988.48 million6.03$76.53 million$3.3135.43

Haemonetics has lower revenue, but higher earnings than Merit Medical Systems. Haemonetics is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Merit Medical Systems and Haemonetics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merit Medical Systems01702.88
Haemonetics00403.00

Merit Medical Systems currently has a consensus target price of $64.3750, indicating a potential upside of 4.13%. Haemonetics has a consensus target price of $144.80, indicating a potential upside of 23.70%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts clearly believe Haemonetics is more favorable than Merit Medical Systems.

Volatility & Risk

Merit Medical Systems has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.

Summary

Haemonetics beats Merit Medical Systems on 9 of the 14 factors compared between the two stocks.

Merit Medical Systems (NASDAQ:MMSI) and Quidel (NASDAQ:QDEL) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

99.5% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 84.0% of Quidel shares are owned by institutional investors. 4.7% of Merit Medical Systems shares are owned by insiders. Comparatively, 14.1% of Quidel shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Merit Medical Systems and Quidel's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merit Medical Systems-3.05%9.02%4.91%
Quidel36.91%63.31%40.55%

Earnings and Valuation

This table compares Merit Medical Systems and Quidel's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$994.85 million3.46$5.45 million$1.4642.36
Quidel$534.89 million10.34$72.92 million$2.7347.87

Quidel has lower revenue, but higher earnings than Merit Medical Systems. Merit Medical Systems is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Merit Medical Systems and Quidel, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merit Medical Systems01702.88
Quidel10302.50

Merit Medical Systems currently has a consensus target price of $64.3750, indicating a potential upside of 4.13%. Quidel has a consensus target price of $262.75, indicating a potential upside of 102.04%. Given Quidel's higher probable upside, analysts clearly believe Quidel is more favorable than Merit Medical Systems.

Volatility & Risk

Merit Medical Systems has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Summary

Quidel beats Merit Medical Systems on 9 of the 14 factors compared between the two stocks.


Merit Medical Systems Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$599.00+0.6%$47.14 billion$2.41 billion27.25
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$303.23+1.1%$22.63 billion$1.84 billion80.01
The Cooper Companies logo
COO
The Cooper Companies
1.9$388.63+0.6%$19.21 billion$2.43 billion80.80
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$65.26+2.2%$13.99 billion$4.03 billion-283.74Decrease in Short Interest
Haemonetics logo
HAE
Haemonetics
1.6$117.28+0.2%$5.97 billion$988.48 million56.66
Quidel logo
QDEL
Quidel
2.4$130.68+0.8%$5.48 billion$534.89 million15.34
STAAR Surgical logo
STAA
STAAR Surgical
1.4$117.85+1.9%$5.38 billion$150.18 million620.30Increase in Short Interest
Neogen logo
NEOG
Neogen
1.2$94.06+0.8%$4.99 billion$418.17 million82.51
ICU Medical logo
ICUI
ICU Medical
1.5$208.36+1.1%$4.37 billion$1.27 billion55.12Insider Selling
Atrion logo
ATRI
Atrion
1.1$649.65+0.7%$1.18 billion$155.07 million36.60
Cerus logo
CERS
Cerus
1.5$6.32+0.9%$1.05 billion$74.65 million-16.20News Coverage
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$24.14+0.6%$1.05 billion$253.67 million22.35
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.30+0.2%$742.48 million$154.60 million-44.78
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.05+0.2%$679.37 million$123.86 million67.51
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.64+0.5%$579.22 million$114.51 million-86.47Gap Down
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$88.57+1.5%$317.93 million$46.90 million27.94
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.